Production (Stage)
Terns Pharmaceuticals, Inc.
TERN
$3.02
$0.082.72%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.71M | 7.95M | 9.77M | 7.19M | 6.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.43M | 25.95M | 24.94M | 25.54M | 25.45M |
| Operating Income | -27.43M | -25.95M | -24.94M | -25.54M | -25.45M |
| Income Before Tax | -23.82M | -21.76M | -21.88M | -22.68M | -22.28M |
| Income Tax Expenses | 88.00K | 40.00K | 62.00K | 61.00K | 97.00K |
| Earnings from Continuing Operations | -23.91M | -21.80M | -21.95M | -22.74M | -22.37M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.91M | -21.80M | -21.95M | -22.74M | -22.37M |
| EBIT | -27.43M | -25.95M | -24.94M | -25.54M | -25.45M |
| EBITDA | -27.37M | -25.88M | -24.86M | -25.45M | -25.36M |
| EPS Basic | -0.26 | -0.24 | -0.28 | -0.31 | -0.30 |
| Normalized Basic EPS | -0.16 | -0.15 | -0.18 | -0.19 | -0.19 |
| EPS Diluted | -0.26 | -0.24 | -0.28 | -0.31 | -0.30 |
| Normalized Diluted EPS | -0.16 | -0.15 | -0.18 | -0.19 | -0.19 |
| Average Basic Shares Outstanding | 91.47M | 91.24M | 77.82M | 74.46M | 74.40M |
| Average Diluted Shares Outstanding | 91.47M | 91.24M | 77.82M | 74.46M | 74.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |